Fresenius Medical Care AG (NYSE:FMS) Shares Sold by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC decreased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,285 shares of the company’s stock after selling 612 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Fresenius Medical Care were worth $731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of FMS. Allworth Financial LP boosted its holdings in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Fresenius Medical Care in the third quarter valued at approximately $38,000. GAMMA Investing LLC grew its position in Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after acquiring an additional 1,675 shares during the period. ORG Wealth Partners LLC acquired a new stake in Fresenius Medical Care during the third quarter worth $112,000. Finally, Venturi Wealth Management LLC raised its position in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares during the period. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Wall Street Analyst Weigh In

FMS has been the subject of a number of recent analyst reports. Berenberg Bank initiated coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Monday, January 6th. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They issued a “strong-buy” rating on the stock. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Stock Down 0.3 %

Shares of NYSE:FMS opened at $23.09 on Friday. The firm has a market capitalization of $13.55 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 0.72 and a beta of 0.92. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm’s 50-day moving average is $22.67 and its two-hundred day moving average is $20.86.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.